Information Provided By:
Fly News Breaks for September 9, 2015
TTPH
Sep 9, 2015 | 07:56 EDT
Wedbush analyst Heather Behanna downgraded Tetraphase Pharmaceuticals to Hold and cut his price target for shares to $11 from $51 after eravacycline failed in a Phase 3 study. Five other firms downgraded shares this morning.
News For TTPH From the Last 2 Days
There are no results for your query TTPH